News
Categories
Sign up
Featured Posts
Archive
- September 2020
- June 2020
- April 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- July 2019
- June 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- May 2018
- April 2018
- March 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- July 2017
- May 2017
- April 2017
- February 2017
- January 2017
Follow Us
The Massachusetts Radiation Control Program (RCP), in conjunction with the U.S. Nuclear Regulatory Commission (NRC), has approved Alpha Tau Medical’s Alpha DaRT cancer treatment as a Sealed Source and Device (SSD). https://www.dotmed.com/news/story/44162 Granting of the certification deems the radiotherapy solution a suitable candidate for clinical trials at U.S. cancer centers in the treatment of various types of solid tumors. Known as Diffusing Alpha-emitters Radiation Therapy, the approach is the first alpha radiation-based cancer treatment for various types of solid tumors. “The Alpha DaRT applicators are designed to ensure that the Alpha DaRT Seeds and the radioactive isotopes will be r
Alpha Tau is in the last stages of raising an investment of several tens of millions of dollars. Israeli oncology company Alpha Tau Medical Ltd. is in the last stages of raising an investment of several tens of millions of dollars, one person familiar with the matter told Calcalist on condition of anonymity. The round is expected to close by the end of the month, that person said. Alpha Tau raised $25 million to date. Cancer tumor (illustration). Photo: medscape Founded in 2016 and headquartered in Tel Aviv, clinical-stage Alpha Tau uses alpha radiation to treat various types of solid tumors. The technique, called Alpha DaRT (Dіffusіng Alpha-emіtters Radіatіon Therapy), was developed by two
Alpha Tau’s High-Precision Cancer Radiotherapy Receives Radioactive-Safety Approval in the United St
The new Sealed Source and Device (SSD) approval enables the commencement of clinical trials in leading hospitals across the U.S. with the company’s breakthrough cancer treatment, Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy). Boston, MA, August 21st 2018 -- Israel MedTech startup, Alpha Tau Medical, is proud to announce that the Massachusetts Radiation Control Program (RCP), under agreement with the U.S. Nuclear Regulatory Commission (NRC), approved the company’s treatment, the Alpha DaRT, as a Sealed Source and Device (SSD). The new approval enables the initiation of clinical trials in leading cancer centers across the U.S which are interested in investigating the Alpha DaRT as a
[..] Another company from Tel Aviv, Alpha Tau Medical, has partnered with Japanese biotechnology startup HekaBio to release radiation therapy equipment in Japan in 2021, at the earliest. The product is designed to treat patients with breast, skin and other solid cancers. Unlike most such equipment, Alpha Tau's "radioactive seeds" emit alpha rays from inside the body. These rays are more powerful than other forms of radiation but are less likely to damage surrounding cells. HekaBio CEO Robert Claar has high hopes the device will prove practical. "We can provide this therapy at lower prices than external radiation therapies," he said. [...]